Now showing items 1-6 of 6
Anti-donor immune responses elicited by allogeneic mesenchymal stem cells and their extracellular vesicles: Are we still learning?
(Frontiers Media, 2017-11-24)
Mesenchymal stromal cells (MSC) have been used to treat a broad range of disease indications such as acute and chronic inflammatory disorders, autoimmune diseases, and transplant rejection due to their potent immunosuppr ...
Regulating immunogenicity and tolerogenicity of bone marrow-derived dendritic cells through modulation of cell surface glycosylation by dexamethasone treatment
(Frontiers Media, 2017-10-30)
Dendritic cellular therapies and dendritic cell vaccines show promise for the treatment of autoimmune diseases, the prolongation of graft survival in transplantation, and in educating the immune system to fight cancers. ...
Mesenchymal stem cell therapy to promote corneal allograft survival: current status and pathway to clinical translation
(Lippincott, Williams & Wilkins, 2016-12)
PURPOSE OF REVIEW: This article reviews the literature on the therapeutic potential of mesenchymal stem cells (MSCs) to prolong corneal allograft survival. RECENT FINDINGS: To date, only small numbers studies have ...
Third-party allogeneic mesenchymal stromal cells prevent rejection in a pre-sensitized high-risk model of corneal transplantation
(Frontiers Media, 2018-11-20)
High-risk cornea transplant recipients represent a patient population with significant un-met medical need for more effective therapies to prevent immunological graft rejection due to heightened anti-donor immune response. ...
TNF-a/IL-1ß-licensed mesenchymal stromal cells promote corneal allograft survival via myeloid cell-mediated induction of Foxp3+ regulatory T cells in the lung.
(Federation of American Society of Experimental Biology (FASEB), 2019-05-20)
Mesenchymal stromal cells (MSCs) have shown promise as a therapy for immune-mediated disorders, including transplant rejection. Our group previously demonstrated the efficacy of pretransplant, systemic administration of ...
Stromal cell PD-L1iInhibits CD8(+) T-cell antitumor immune responses and promotes colon cancer
(American Association for Cancer Research, 2018-11)
Stromal cells of mesenchymal origin reside below the epithelial compartment and provide structural support in the intestine. These intestinal stromal cells interact with both the epithelial cell compartments, as well as ...